| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1 |
| Entrez GeneID | 29126 |
| clone | 7D2A10 |
| WB Predicted band size | 33.3kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD274 (AA: 24-153) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD274(PD-L1)抗体的3篇模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**: *"Targeting PD-L1 for Cancer Immunotherapy: Mechanisms and Clinical Progress"*
**作者**: Smith A, et al.
**摘要**: 本文综述了PD-L1抗体在肿瘤免疫治疗中的作用机制，包括阻断PD-1/PD-L1通路以恢复T细胞活性，并总结了多项临床试验中抗PD-L1单抗(如Atezolizumab)在非小细胞肺癌和黑色素瘤中的疗效与安全性。
2. **文献名称**: *"Structural Basis of PD-L1 Recognition by Therapeutic Antibodies"*
**作者**: Zhang Y, et al.
**摘要**: 通过X射线晶体学解析了PD-L1蛋白与多种治疗性抗体的结合表位，揭示了抗体通过空间位阻效应阻断PD-1/PD-L1相互作用的分子机制，为优化抗体设计提供了结构学依据。
3. **文献名称**: *"PD-L1 Expression as a Predictive Biomarker for Anti-PD-L1 Therapy Response"*
**作者**: Johnson R, et al.
**摘要**: 研究探讨了肿瘤组织PD-L1表达水平与抗PD-L1抗体治疗反应的相关性，发现高表达患者客观缓解率显著提高，但部分低表达患者仍可受益，提示需结合其他生物标志物优化治疗方案。
---
(注：如需真实文献，可检索PubMed等数据库，关键词如“anti-PD-L1 antibody”、“CD274 immunotherapy”。)
CD274. also known as programmed death-ligand 1 (PD-L1), is a transmembrane protein belonging to the B7 family of immune checkpoint molecules. It plays a critical role in modulating immune responses by binding to its receptor PD-1 (programmed cell death protein 1) on T cells, thereby suppressing T-cell activation and promoting immune tolerance. Tumors often exploit this pathway by overexpressing PD-L1 to evade immune surveillance, enabling uncontrolled growth and metastasis. Targeting the PD-1/PD-L1 axis has emerged as a groundbreaking strategy in cancer immunotherapy.
CD274 antibodies are monoclonal antibodies designed to block the interaction between PD-L1 and PD-1. effectively "releasing the brakes" on T cells and restoring their anti-tumor activity. Since the first FDA approval of anti-PD-L1 agents like atezolizumab (2016), durvalumab, and avelumab, these therapies have transformed treatment paradigms for various cancers, including non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. Beyond oncology, PD-L1 antibodies are being explored in infectious diseases and autoimmune conditions due to their immunoregulatory properties.
Clinically, CD274 antibodies are often used as monotherapy or combined with chemotherapy, radiation, or other immunotherapies. Their efficacy correlates with tumor PD-L1 expression levels, which are assessed via companion diagnostic assays. However, challenges persist, including variable response rates, acquired resistance, and immune-related adverse events. Ongoing research focuses on optimizing patient selection, identifying predictive biomarkers, and developing next-generation agents with improved safety profiles.
×
